ArticlePlant biotechnology journal2025
QCAV-4, the first genetically modified Cavendish (cv. Grand Nain) banana resistant to Fusarium wilt tropical race 4 approved for commercial production and consumption.
Article in Plant biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Transgene-Free, Gene-Edited Cavendish Bananas (Musa acuminata, AAA).Plant biotechnology journal · 2026Article
- Chromosomal deletions in banana somaclonal variants reveal negative regulators of immunity underlyingProceedings of the National Academy of Sciences of the United States of America · 2025Article
- A RUBY Reporter for Efficient Banana Transformation and Development of Betalain-RichInternational journal of molecular sciences · 2025Article
- Histological and transcriptome analysis uncover a robust early PTI and ETI-associated immune response inFrontiers in plant science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bananas (Musa spp.) are a major fruit crop worldwide, with the Cavendish cultivar dominating the export industries, which are based primarily in the Americas and the Philippines. The sustainability of banana production in these, and other regions, is under threat from the fungal disease Fusarium wilt tropical race 4 (TR4) which kills Cavendish and many other banana cultivars. No effective TR4 control strategies exist, and no consumer-acceptable TR4-resistant Cavendish replacements are currently available. Previously, we identified four genetically modified (GM) TR4-resistant Cavendish (cv. Grand Nain) banana lines (RGA2-2, -3, -4, and -5), each transformed with the MamRGA2 resistance gene derived from a TR4-resistant wild banana. Here, we provide a comprehensive agronomic evaluation of these lines and report the regulatory approval of the top-performing line, RGA2-4 (QCAV-4), in Australia. After five crop cycles of field trialling, TR4 disease incidence reached 66% and 84% in the Grand Nain and Williams non-GM controls, respectively, while GM lines showed a significantly reduced incidence ranging from 2% (QCAV-4) to 36% (RGA2-5). Agronomic comparisons between QCAV-4 and non-GM Grand Nain controls for bunch weight, yield and cycle time indicated that, for most crop cycles, there were no differences, showing that, apart from TR4 resistance, QCAV-4 is agronomically and phenotypically comparable to conventional Grand Nain. Molecular characterization of QCAV-4 confirmed a single, large T-DNA insert containing multiple copies of the MamRGA2 gene on chromosome 6 of the QCAV-4 genome. QCAV-4 is the first GM banana approved for commercial cultivation and consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.